We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00681369
First Posted: May 21, 2008
Last Update Posted: January 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
May 20, 2008
May 21, 2008
January 24, 2011
May 2007
Not Provided
  • Evaluate Faslodex therapeutic strategy and treatment duration [ Time Frame: At the end of the study ]
  • Describe the characteristics of patients treated with Faslodex [ Time Frame: At the end of the study ]
Same as current
Complete list of historical versions of study NCT00681369 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Hospital sample
Breast Cancer
Not Provided
1
Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
217
June 2007
Not Provided

Inclusion Criteria:

  • Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Sexes Eligible for Study: Female
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00681369
NIS-OFR-FAS-2007/1
No
Not Provided
Not Provided
Francisco Sapunar - Medical Science Director, AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Alain FLINOIS TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge
AstraZeneca
January 2011